Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Although customization is a popular initiative among the competition, AB is already one of the largest providers of custom target-date funds in the US, and its capabilities in managing and ...

Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.

Companies that have increased their book values and have low Price to Earnings Ratio ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...